Temozolomide-associated organizing pneumonitis

Fabien Maldonado, Andrew H. Limper, Kaiser G. Lim, Marie Christine Aubry

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.

Original languageEnglish (US)
Pages (from-to)771-773
Number of pages3
JournalMayo Clinic proceedings
Issue number6
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Temozolomide-associated organizing pneumonitis'. Together they form a unique fingerprint.

Cite this